当前位置: 首页 > 期刊 > 《中国医学创新》 > 2024年第3期
编号:1693872
Nur77在肺癌中的研究进展
http://www.100md.com 2024年5月12日 中国医学创新 2024年第3期
     韩谊 莫黎芳 李小玲 覃春艳 蒋玉洁

    【摘要】 核受体Nur77是立早基因NR4A1编码的产物,在包括肺癌在内的多种肿瘤组织中表达,并广泛参与肿瘤的生物学进程。肺癌发病率高,发病机制复杂,早期不易发现,治疗效果差,是人类常见的恶性肿瘤之一。大量研究显示Nur77在肺癌发生发展、侵袭转移、凋亡、免疫调节及治疗等方面扮演着重要角色。本文主要概述Nur77在肺癌中的研究进展。

    【关键词】 Nur77 NR4A1 肺癌

    Research Progress of Nur77 in Lung Cancer/HAN Yi, MO Lifang, LI Xiaoling, QIN Chunyan, JIANG Yujie. //Medical Innovation of China, 2024, 21(03): -155

    [Abstract] The nuclear receptor Nur77 is a product encoded by the immediate early gene NR4A1, which is expressed in various tumor tissues including lung cancer, and is widely involved in the biological process of tumors. Lung cancer is one of the common human malignant tumors with high incidence, complex pathogenesis, difficult to find in the early stage and poor treatment effect. A large number of studies have shown that Nur77 plays an important role in the development, invasion and metastasis, apoptosis, immune regulation and treatment of lung cancer. This article reviews the research progress of Nur77 in lung cancer.

    [Key words] Nur77 NR4A1 Lung cancer

    First-author's address: Department of Respiratory and Critical Care Medicine ......

您现在查看是摘要页,全文长 21962 字符